Heking Pharmaceutical Technology

Heking Med is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focused on the discovery and development of innovative small molecule therapeutics for oncology and autoimmune diseases. The company leverages its internal R&D capabilities to target well-validated pathways such as MET, FGFR, and JAK, with a primary focus on addressing unmet medical needs in solid tumors and inflammatory conditions. Its lead candidate, HK-010, is a highly selective MET inhibitor currently undergoing clinical evaluation for various cancers. Heking Med aims to provide high-quality, affordable precision medicines through a combination of independent innovation and strategic collaborations.